Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improves Lung Function, Asthma Control: Daily Dose
Your daily dose of the clinical news you may have missed.
Semaglutide Shows Potential for Significant CVD Prevention in Analysis of Real-World Data
Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.
Salt Substitute Reduces HTN Risk among Older Adults with Normal BP: Daily Dose
8 Questions on the 2024 GOLD COPD Guidelines: A Quiz for Primary Care
Test your COPD IQ with these 8 questions on spirometry in COPD diagnosis, COPD exacerbations and treatment response, when to add ICS, and other topics for PCPs.
Viking Therapeutics Dual GIP/GLP-1 Mimetic Drives Weight Loss of Up to 14.7% in Phase 2 Findings
Viking's VENTURE trial met primary and all secondary endpoints, with GI-related TAEAs reported as mild/moderate and diminishing over the course of the 13-week study.
Atogepant Safe and Effective in Treatment-Resistant Episodic Migraine: ELEVATE Phase 3b Trial
Atogepant once daily reduced mean monthly headache days in adults for whom up to 4 classes of oral migraine preventives were ineffective.
Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers
AAAAI 2024. Needle phobia is just one of the barriers to not just using an epinephrine autoinjector but to carrying one at all, according to 2 sets of surveys findings.
Survodutide, Dual Glucagon/GLP-1 Mimetic, Improves MASH in 83% of Phase 2 Trial Participants
The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.
First-Ever Long COVID Tissue Bank Launched at University of California San Francisco
"Viral reservoirs" in human tissue may preserve the SARS-CoV-2 virus, provoking an immune response that could drive long COVID-associated symptoms.
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares
AAAAI 2024. In patients with treatment-resistant chronic spontaneous urticaria, neffy 1 mg and 2 mg resulted in improvement in itch, hives, urticaria, and erythema scores 5 minutes after dosing.
Impact of Regular Exercise on Hospitalization in Patients with COPD: Daily Dose
Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA
neffy (epinephrine nasal spray) delivered a PK and PD profile greater than or similar to that of IM epinephrine after extreme nasal challenge, reports ARS Pharmaceuticals.
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.
Lowering Out-of-Pocket Rx Costs May Improve Diabetes Outcomes: Daily Dose
EoE in Children Treated with Dupilumab More Severe at Diagnosis, Study Finds
AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.
FDA Accepts Dupilumab sBLA for Priority Review for Treatment of COPD with Type 2 Inflammation
A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.
How do Americans Handle Being Sick?
A recent survey reveals some surprising facts about who handles illness better - men or women.
New Research Highlights Specific Allergens that May Predispose Sensitized Children with Asthma to Upper Respiratory Infections
AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.
New neffy Data on Clinical Efficacy Presented at 2024 AAAAI Annual Meeting
AAAAI 2024. New data on neffy (epinephrine nasal spray) include the first report of efficacy after oral food challenge in a pediatric population at risk for anaphylaxis.
Weight Management Treatments Underused among Primary Care Patients with Obesity: Daily Dose
